The FDA approval of Abbott’s Confirm Rx marks the green light for the first smartphone-compatible insertable cardiac monitor. With it, abnormal heartbeats can be diagnosed without a separate recording device, the company said.
A new imaging system using continuous-mapping technology also got FDA clearance for catheter ablation. The AcQMap High Resolution Imaging and Mapping System allows electrophysiologists map and re-map quickly for better visualization. (Healio)
Femoral access for transcatheter aortic valve replacement (TAVR) resulted in the loss of common femoral artery integrity, according to a study in Catheterization and Cardiovascular Interventions. Researchers observed significant minimum luminal diameter reduction and diameter stenosis increase after the procedure.
After TAVR, patients had more left ventricular mass index regression and fewer deaths if they started taking angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, a registry study found. (Heart)
Two catheters exhibited certain trade-offs in the setting of non-urgent coronary angiography via transradial approach: the Tiger-II saved on contrast volume and fluoroscopy time and was better for right coronary artery imaging, while the Judkins had the upper hand for visualizing the left anterior descending and left circumflex arteries. (EuroIntervention)
The Virtue sirolimus-eluting balloon conferred 100% procedural success in patients with in-stent restenosis, a first-in-human study in JACC: Cardiovascular Interventions showed. Zero safety events occurred in the first 30 days, and in-segment late lumen loss reached 0.31 mm by month 6.
DNA damage markers soared in operators performing endovascular aortic repair, presumably from radiation exposure. Leg shielding neutralized the damage response. (Circulation)